Monoclonal antibody Ber‐EP4 reliably discriminates between microcystic adnexal carcinoma and basal cell carcinoma

2007103 citationsJournal Article

Authors

Dieter Krahl · Institut für Hämatopathologie Hamburg

Abstract

Ber-EP4 reliably differentiates microcystic adnexal carcinoma from basal cell carcinoma to the same extent as it distinguishes the latter tumor from squamous cell carcinoma. While it stains the majority of desmoplastic trichoepitheliomas, these tumors still have to be considered in the differential diagnosis with microcystic adnexal carcinoma, when Ber-EP4 is applied.

Topics & Keywords

Cancer and Skin Lesions Nonmelanoma Skin Cancer Studies Tumors and Oncological Cases

UN Sustainable Development Goals

Reduced inequalities

Publication Details

Published in: Journal of Cutaneous Pathology

Volume 34, Issue 10, pp. 782-787

DOI: 10.1111/j.1600-0560.2006.00710.x

Field-Weighted Citation Impact: 7.50